28 jun: Når lav risiko giver højt afkast
17 jul: Test
03-07-2012 21:09:00

UPDATE: FDA Approves OraSure's Over-The-Counter Home HIV Test

Relateret indhold
Relateret debat
29 okt - 
Amazon vil til at bringe insulin ud med droner.
29 okt - 
Amazon har fået godkendt medicinsælger-status i i 12 st..
28 okt - 
Rygtet var ude for et par dage siden og allerede rykket..

--FDA approves first HIV test to be sold in retail stores

--Test will be available in October

--Home test appears to be not as accurate as tests by health professionals

(Adds company comments on test availability, pricing, in the third and fourth paragraphs.)

By Jennifer Corbett Dooren

WASHINGTON--The Food and Drug Administration Tuesday approved a home HIV test that will be sold in retail stores so people wouldn't have to go to a health facility to learn if they have the virus.

The test, made by OraSure Technologies Inc. (OSUR), has been available to health-care professionals. The test, called the OraQuick In-Home HIV test, uses a mouth swab to collect saliva. The swab is then inserted into a test tube where results are made available within a 20-to-40 minute time frame.

Company officials said the test will be available in October and sold at more than 30,000 retailers such as Wal-Mart Stores Inc. (WMT) and large grocery and drug-store chains including CVS Caremark Corp. (CVS), Rite Aid Corp. (RAD) and Walgreen Co. (WAG). The test will also be sold online.

OraSure said a price hasn't been established but it will be slightly higher than the $17.50 currently paid by health-care professionals, to fund additional labeling costs and a customer-support center.

The FDA said a positive result needs to be confirmed with a follow-up test in a health-care facility. The agency also said negative readings don't necessarily mean people aren't infected with HIV because the test might not be able to pick up infections within three months before testing.

Still, the agency said the test has the potential to identify large numbers of previously undetected HIV infections, especially if used by people unlikely to use standard screening methods.

About 1.2 million people in the U.S. are infected with HIV, and about 50,000 infections are diagnosed each year, a level that has been stable for a decade. Federal health officials have estimated that 20% of people with HIV don't realize they are infected and risk spreading the virus, which causes AIDS.

"Knowing your status is an important factor in the effort to prevent the spread of HIV," said Dr. Karen Midthun, director of FDA's Center for Biologics Evaluation and Research. "The availability of a home-use HIV test kit provides another option for individuals to get tested so that they can seek medical care, if appropriate."

However, there is one concern about the home test: Clinical testing has showed it doesn't appear to be as accurate as tests conducted by health professionals.

One measure of the test's accuracy in the home setting showed it had a sensitivity rate of 92%. The FDA said this means there would be one false negative test result for every 12 tests taken in HIV-infected individuals.

The FDA said one false positive result would be expected out of every 5,000 test results taken by uninfected individuals.

Write to Jennifer Corbett Dooren at jennifer.corbett@dowjones.com.

(END) Dow Jones Newswires

July 03, 2012 15:09 ET (19:09 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Genmab/IR: Royalties vil som minimum dække omkostningerne næste år

12-12-2017 14:04:43
Genmabs royaltyindtægter fra salget af selskabets kræftmidler vil i 2018 som minimum dække omkostningerne.Det præciserer Genmabs IR- og kommunikationsdirektør, Rachel Curtis Gravesen, i en e-mail over for Ritzau Finans, efter at selskabet i nattens løb er kommet med en foreløbig prognose for 2018, som angiveligt har givet anledning til en del tolkning i analytikerkredse vedrørende salget af Genmab..

Aktier/middag: Genmab ryger ned på usikkerhed om 2018-forventninger

12-12-2017 11:39:38
Genmab er under hårdt pres på det danske aktiemarked tirsdag, da flere investorer har tolket negativt på ledelsens udmeldinger om 2018 og nu regner med et lavere salg af kræftmidlet Darzalex end tidligere.Aktien dykker 7,7 pct. til 1093 kr. - det største fald i små to år - og nedturen for biotekaktien er med til at tynge C20 Cap-indekset, som dykker 0,3 pct. til 1125,54.Genmab afholdt natten til t..

Aktier/tendens: SAS klar med endelige regnskabstal før handelsstart

12-12-2017 08:15:47
Luftfartsselskabet SAS offentliggjorde forud for børsåbningen tirsdag sit endelige regnskab for det skæve regnskabsår 2016/17, og selskabet kan derfor løbe med en del af opmærksomheden ved handelsstart.Det danske aktiemarked kan gå endnu en grøn dag i møde på det ledende eliteindeks, hvis den amerikanske grønne bølge forplanter sig på de europæiske markeder.Mandag fik C20 Cap-indekset en positiv s..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Genmab/Jefferies: Svært at se væsentlig konkurrencerisiko
2
Genmab-aktien får kurstæsk efter forsigtig udmelding fra ledelsen
3
Genmab-aktien får kurstæsk efter forsigtig udmelding fra ledelsen - NY
4
Novo-rival for godkendt kopiprodukt
5
Ørsted opjusterer forventninger efter delvist salg af havmøllepark -NY

Relaterede aktiekurser

CVS Health Corporation 73,08 0,0% Aktiekurs uændret
Rite Aid Corporation 1,89 0,0% Aktiekurs uændret
Wal-Mart Stores Inc 96,93 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
12. december 2017 15:20:34
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171124.1 - EUROWEB4 - 2017-12-12 15:20:34 - 2017-12-12 15:20:34 - 1 - Website: OKAY